Elicio Therapeutics Inc (ELTX)

Currency in USD
8.02
-0.06(-0.74%)
Closed·
8.03+0.01(+0.12%)
·
ELTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.958.13
52 wk Range
4.6012.62
Key Statistics
Prev. Close
8.08
Open
8.07
Day's Range
7.95-8.13
52 wk Range
4.6-12.62
Volume
67.56K
Average Volume (3m)
98.92K
1-Year Change
59.44%
Book Value / Share
0.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.50
Upside
+93.27%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Elicio Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Elicio Therapeutics Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Compare ELTX to Peers and Sector

Metrics to compare
ELTX
Peers
Sector
Relationship
P/E Ratio
−3.1x−4.9x−0.6x
PEG Ratio
−0.11−0.050.00
Price/Book
36.7x6.5x2.6x
Price / LTM Sales
-13,691.6x3.2x
Upside (Analyst Target)
91.8%196.9%41.8%
Fair Value Upside
Unlock3.1%5.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.50
(+93.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy18.00+124.44%12.00Maintain17/09/2025
H.C. Wainwright
Buy13.00+62.09%10.00Maintain17/07/2025
Jones Trading
Buy12.00+49.63%9.00Maintain06/03/2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.60 / -0.68
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

14.15
AARD
-2.75%
5.94
CAMP
-1.00%
8.88
KYTX
+9.23%
154.50
BLTE
-0.64%

FAQ

What Is the Elicio Therapeutics (ELTX) Share Price Today?

The live Elicio Therapeutics share price today is 8.02

What Stock Exchange Does Elicio Therapeutics (ELTX) Trade On?

Elicio Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Elicio Therapeutics?

The stock symbol (also called a 'ticker') for Elicio Therapeutics is "ELTX."

What Is the Current Elicio Therapeutics Market Cap?

As of today, Elicio Therapeutics market capitalisation is 140.15M.

What Is Elicio Therapeutics's (ELTX) Earnings Per Share (TTM)?

The Elicio Therapeutics EPS is currently -3.09 (Trailing Twelve Months).

Is ELTX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Elicio Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Elicio Therapeutics Stock Split?

Elicio Therapeutics has split 0 times. (See the ELTX stock split history page for full effective split date and price information.)

How Many Employees Does Elicio Therapeutics Have?

Elicio Therapeutics has 32 employees.

What is the current trading status of Elicio Therapeutics (ELTX)?

As of 24 Dec 2025, Elicio Therapeutics (ELTX) is trading at a price of 8.02, with a previous close of 8.08. The stock has fluctuated within a day range of 7.95 to 8.13, while its 52-week range spans from 4.60 to 12.62.

What Is Elicio Therapeutics (ELTX) Price Target According to Analysts?

The average 12-month price target for Elicio Therapeutics is USD15.5, with a high estimate of USD18 and a low estimate of USD13. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +93.27% Upside potential.

What Is the ELTX After Hours Price?

ELTX's last after hours stock price is 8.03, the stock has decreased by 0.01, or 0.12%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.